Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Morgan Stanley (NYSE:MS) has raised its price target on Pfizer (NYSE:PFE) stock to $33.00 from $32.00 while maintaining an Equalweight rating on the pharmaceutical giant. According to InvestingPro data, Pfizer currently trades at $24.73, with analysts’ targets ranging from $23.00 to $37.80, suggesting potential upside. The stock appears undervalued based on InvestingPro’s Fair Value analysis.
The adjustment follows Pfizer’s recent earnings report, during which the company provided perspective on the evolving biopharmaceutical policy landscape.
Morgan Stanley noted that Pfizer’s guidance includes potential price changes this year based on the President’s recent letter, though the company provided limited details on the matter.
The investment firm made adjustments to its estimates for Pfizer based on this information, but ultimately decided to maintain its Equalweight stance on the stock.
Pfizer continues to navigate policy changes in the pharmaceutical sector while managing investor expectations regarding potential pricing impacts on its business outlook.
In other recent news, Pfizer Inc. reported impressive financial results for the second quarter of 2025. The company’s earnings per share (EPS) came in at $0.78, significantly surpassing analyst forecasts of $0.57, marking a 36.84% surprise. Pfizer’s revenue also exceeded expectations, reaching $14.7 billion compared to the anticipated $13.47 billion. These results highlight the company’s strong performance during this period. Additionally, the positive earnings announcement led to a notable reaction in the stock market. Analysts from various firms have taken note of Pfizer’s robust financial results, although no specific upgrades or downgrades were mentioned in recent reports. Investors are closely watching these developments as they assess Pfizer’s ongoing business strategies. These recent updates provide valuable insights into Pfizer’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.